Clemens van Blitterswijk is the founder of RegMed XB and chairs the Scientific Board. He also combines his Professorship at Maastricht University with a Founding Partnership of the LSP-Health Economics Fund (LSP-HEF) of the European health care investment group. He received his PhD degree from Leiden University in 1985 and he worked as an Associate Professor at the Department of Biomaterials at Leiden University. In 1997 he moved to University of Twente and functions as Professor at the Department of Tissue Regeneration. Since 2014 he became University Professor at MERLN institute, Maastricht University.
Van Blitterswijk has acted on numerous national and international advisory boards relating directly to either life and material sciences or to the economic applications thereof. He has held various positions in these organizations including chairman of the Dutch Society for Biomaterials, treasurer of the European Society for Biomaterials, and council member of TERMIS. During his career, he has co-founded multiple biomedical companies and held several functions in these organizations.
Professor Peter Carmeliet is head of the Laboratory of Angiogenesis and Vascular Metabolism at the VIB-KU Leuven Center for Cancer Biology, Department of Oncology KU Leuven, Belgium and former director of the VIB-Vesalius Research Center. He graduated as Doctor in Medicine in 1984, completed his PhD in 1989, and performed a postdoctoral training at the Whitehead Institute, MIT in Cambridge USA. After his return to Leuven in 1992, Dr. Carmeliet started his own research group with a focus on how blood vessels grow (angiogenesis) in health and disease. Dr. Carmeliet has published over 618 articles (>69,000 citations, h-index: 120). His achievements have been recognized by several honors and awards.The Carmeliet lab is currently studying how endothelial cells change their metabolism during vascular branching and exploring the therapeutic potential of targeting endothelial metabolism for anti-angiogenic strategies. The role of several key metabolic targets in endothelial cell biology and angiogenesis in vivo is under investigation.
Frank P. Luyten, MD, PhD is board certified Rheumatologist, tenured full Professor and Head of the Division of Rheumatology at the University Hospitals Leuven; Director of the Skeletal Biology & Engineering Research Center, KU Leuven and of Prometheus, the Tissue Engineering Division at the KU Leuven. He obtained his MD, PhD degree and Board Certification in Rheumatology at the University of Ghent, Belgium. He spent his Postdoctoral Training at the National Institute of Dental Research, National Institutes of Health, Bethesda, MD, USA. He became subsequently group leader of the Developmental Biology Unit at the Bone Research Branch, NIDR, NIH, Bethesda, USA. Frank Luyten is also founder, scientific and medical advisor of TiGenix, a Biotech spin-off of the Universities of Leuven and Ghent. He serves as advisor and board member of several biotech companies in the field of Regenerative Medicine.
Bert Meijer is Distinguished University Professor in the Molecular Sciences, Professor of Organic Chemistry at the Eindhoven University of Technology and scientific director of the Institute for Complex Molecular Systems. After receiving his PhD degree at the University of Groningen, he worked for 10 years in industry (Philips and DSM). In 1991 he was appointed in Eindhoven, where he supervised over 75 PhD students. In the meantime he has held part-time positions in Nijmegen and Santa Barbara, CA. Bert Meijer is a member of many editorial advisory boards, including Advanced Materials, Angewandte Chemie, and the Journal of the American Chemical Society. Bert Meijer has received a number of awards, including the Spinoza Award in 2001, the ACS Award for Polymer Chemistry in 2006, the AkzoNobel Science Award 2010, the International Award of the Society of Polymer Science Japan in 2011, the Cope Scholar Award of the ACS in 2012, and the Prelog medal in 2014. He is a member of a number of academies and societies, including the Royal Netherlands Academy of Science, where he is appointed to Academy Professor in 2014.
Ton J Rabelink, MD, PhD, is professor of Medicine at the Leiden University Medical Center. He received his MD PhD degree from Utrecht University. After completing his residency and fellowships in internal medicine and nephrology he joined faculty of Utrecht Medical School in 1993. He subsequently became chairman of medicine in the University Hospital Utrecht from 1999 to 2004.
In 2004 he moved to Leiden University Medical Center and became head of the department of Nephrology and Transplantation and in 2010 chairman of Medicine again.
His main research interest has been in the area of vascular biology and its implications for renal function, and in regenerative therapies for kidney disease and diabetes. He coordinates the European-Australian consortium on stem cell based therapy for kidney disease (STELLAR) and is leading the Dutch National Science Agenda for regenerative medicine.